My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Bristol-Myers Squibb (NY:BMY)

54.19 +0.86 (+1.61%)

Official Closing Price Updated: 7:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

84 85 Next >

Better Growth Play: Merck or The Vanguard Growth Index Fund? ↗

April 15, 2024

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

Via The Motley Fool

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom ↗

April 12, 2024

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

Via Benzinga

Peering Into Bristol-Myers Squibb's Recent Short Interest ↗

April 12, 2024

Via Benzinga

Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024 ↗

April 12, 2024

If you’re wondering where to invest in a stock picker's market, these three Warren Buffett stocks are a good place to start.

Via InvestorPlace

This Is What Whales Are Betting On Bristol-Myers Squibb ↗

April 11, 2024

Via Benzinga

If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names ↗

April 11, 2024

Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments.

Via InvestorPlace

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗

April 11, 2024

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Via InvestorPlace

The Pharmaceutical Industry Finds Itself At A Historical Crossroads ↗

April 10, 2024

Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:

Via Benzinga

2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist ↗

April 10, 2024

These reliable dividend payers offer yields of 3.3% and better at recent prices.

Via The Motley Fool

3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade ↗

April 09, 2024

Income-seeking investors can look forward to steady payout raises from these pharma stocks.

Via The Motley Fool

Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation ↗

April 08, 2024

Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA...

Via Benzinga

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

April 08, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics ↗

April 08, 2024

Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts...

Via Benzinga

Down 75%. Is Agenus Stock a Buy on the Dip? ↗

April 08, 2024

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

Via The Motley Fool

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

April 06, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

April 06, 2024

From Bristol Myers Squibb

Via Business Wire

The 3 Most Undervalued Biotech Stocks to Buy in April 2024 ↗

April 05, 2024

The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines.

Via InvestorPlace

FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer ↗

April 05, 2024

FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard...

Via Benzinga

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

April 05, 2024

From Bristol Myers Squibb

Via Business Wire

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? ↗

April 03, 2024

These stocks could rocket higher, but they also present significant risks.

Via The Motley Fool

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

April 02, 2024

From Bristol Myers Squibb

Via Business Wire

Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts ↗

April 02, 2024

With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets.

Via InvestorPlace

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

April 02, 2024

From Bristol Myers Squibb

Via Business Wire

The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains ↗

April 01, 2024

Uncover strategic moves by three pharma giants poised to capture trends and fulfill emerging healthcare needs.

Via InvestorPlace

One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details ↗

April 01, 2024

Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati...

Via Benzinga

The 3 Best Biotech Stocks to Buy in Q2 2024 ↗

March 29, 2024

Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.

Via InvestorPlace

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…

March 28, 2024

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease

March 28, 2024

From Bristol Myers Squibb

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 28, 2024

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

84 85 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.